Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
FUS with Panobinostat in Pediatric DMG
NCT04804709Phase 1Terminated
- Sponsor
- Columbia University
- Start
- Jul 2021
- Primary completion
- Mar 2022
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of panobinostat in diffuse midline glioma (DMG), sponsored by Columbia University. Primary endpoint: Number of Adverse Events up to 7 months. Started Jul 2021; status: terminated.
02
Drugs
panobinostat
03
Conditions
diffuse midline glioma (DMG)
Beyond the preview
Go deeper on NCT04804709.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04804709.